Senseonics Holdings, Inc. conducted its fourth quarter and full year 2025 earnings call on March 2, 2026. The conference featured company executives and analysts discussing financial results. Forward-looking statements were highlighted with standard risk disclosures.
Senseonics Holdings, Inc. (SENS), a medical technology company, hosted its Q4 2025 earnings conference call on March 2, 2026, at 4:30 PM EST. The event was moderated by an operator who provided instructions for participants and noted that the call would be recorded.
Jeremy Feffer, Managing Director at LifeSci Advisors, opened the proceedings. He reminded listeners that the company's remarks included forward-looking statements reflecting management's expectations on future events, operating plans, regulatory matters, product enhancements, and performance. These statements, he explained, are subject to risks and uncertainties detailed in the company's annual report on Form 10-K for the year ended December 31, 2025, as well as 10-Q filings and other SEC reports available on the Investor Relations section of www.senseonics.com. The company stated it has no obligation to update these statements except as required by law.
Company participants included Tim Goodnow, President, CEO, and Director; Brian Hansen, Chief Commercial Officer and Director; and Frederick Sullivan, CFO, Secretary, and Treasurer. Analysts joining the call were Anthony Petrone from Mizuho Securities USA LLC, Joshua Jennings from TD Cowen, Matthew Miksic from Barclays Bank PLC, Marie Thibault from BTIG, LLC, Jonathan Block from Stifel, Nicolaus & Company, Benjamin Haynor from Lake Street Capital Markets, and Xun Lee from H.C. Wainwright & Co.
The call focused on Senseonics' financial performance for the quarter and year, though specific results were not detailed in the introductory segment. Investors can access the full transcript and related documents via the company's website.